Huahai Pharmaceutical shares fluctuate as company reports normal operations

Zhejiang Huahai Pharmaceutical Company Limited announced that its shares experienced abnormal fluctuations, with the cumulative deviation in closing prices exceeding 20% over three consecutive trading days: August 28, August 29, and September 1, 2025. This falls under the definition of abnormal stock trading according to Shanghai Stock Exchange trading rules.

Following an internal review and inquiries with its controlling shareholder and actual controller, the company confirmed that as of the announcement date, there are no unannounced material matters or significant information that should have been disclosed. The company’s production and operations remain normal, with no major changes in market environment or industry policies.

The company's semi-annual report for 2025, disclosed on August 26, 2025, reported a net profit attributable to shareholders of RMB 40,948.76 million, a decrease of approximately 45.30% compared to the same period last year. Net profit attributable to shareholders, excluding non-recurring gains and losses, was RMB 36,342.46 million, down approximately 52.48% year-on-year. Investors are advised to be aware of the secondary market trading risks.